Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 24, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...

Company Drug

Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA

Fineline Cube Jul 24, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...

Company Deals

Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328

Fineline Cube Jul 24, 2024

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...

Company Deals

Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies

Fineline Cube Jul 24, 2024

Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...

Company Deals

Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China

Fineline Cube Jul 24, 2024

Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Deals

TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain

Fineline Cube Jul 24, 2024

TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has...

Company Drug

ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study

Fineline Cube Jul 24, 2024

ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has...

Company

Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs

Fineline Cube Jul 24, 2024

Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...

Policy / Regulatory

China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines

Fineline Cube Jul 23, 2024

The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates...

Company Drug

Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial

Fineline Cube Jul 23, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...

Company Deals

Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine

Fineline Cube Jul 23, 2024

Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a...

Company Drug

China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies

Fineline Cube Jul 23, 2024

Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...

Company Deals

Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy

Fineline Cube Jul 23, 2024

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...

Company Drug

Johnson & Johnson Pursues FDA Approval for Spravato as Monotherapy for Treatment-Resistant Depression

Fineline Cube Jul 23, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading global healthcare company, is pursuing expanded approval...

Company Policy / Regulatory

WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations

Fineline Cube Jul 23, 2024

Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...

Company

Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222

Fineline Cube Jul 23, 2024

UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021,...

Company Deals

China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics

Fineline Cube Jul 23, 2024

Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...

Company Drug

RemeGen’s Telitacicept Earns Full NMPA Approval for RA Treatment and PMN Clinical Study Green Light

Fineline Cube Jul 23, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has announced that the National Medical...

Policy / Regulatory

NMPA Suspends Import and Sale of SAMO S.p.A Knee and Hip Prosthesis Systems

Fineline Cube Jul 23, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Deals

Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development

Fineline Cube Jul 23, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...

Posts pagination

1 … 371 372 373 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.